| 1 |
Author(s):
ANTONIO, LUCA, ANDREA, ANTONELLA, SEBASTIANO, MARIANGELA.
Page No :
|
SEQUENTIAL VOLUMETRIC MODULATED ARC THERAPY (VMAT) BOOST IN HYBRID PLAN WITH TANGENTIAL BEAMS FOR WHOLE BREAST TREATMENT: A DOSIMETRIC STUDY
Abstract
Purpose
Whole breast radiation therapy (WBRT) with a boost to the tumor bed following conservative primary surgery in women with breast cancer (BC) plays a central role in reducing local recurrences and mortality.
Volumetric modulated arc therapy (VMAT) technique has been shown to allow better dose conformation with low dose levels to organs at risk (OARs), compared to static fields three-dimensional Conformal Radiotherapy (3D-CRT).
Aim of this study was to evaluate the feasibility and dosimetric advantages of sequential boost (SB), administered with VMAT technique in hybrid plans with tangential beams for whole breast treatment.
Material and methods
BC patients undergoing adjuvant RT from June to October 2020 were selected.
ESTRO guidelines for the Clinical Target Volume (CTV) delineation were used. Total delivered dose was 60-66 Gy; 50 Gy in 2 Gy daily fractions for whole breast and 10-16 in 2 Gy daily fractions Gy to tumor bed was 10-16 Gy in 2 Gy daily fractions.
Results
The analysis included 31 patients with BC treated with adjuvant RT following conservative surgery.
Hybrid treatment plans characterized by a 3D-CRT plan using tangential mediolateral and lateromedial fields for the irradiation of the whole breast Planning Target Volume (PTV) and a sequential VMAT plan with 2 coplanar arches for boost PTV irradiation were generated.
As regarding to organs at risks (OARs), contralateral breast, ipsi- and contro-lateral lung and heart costraints values were analysed.
Conclusions
In the frame BC RT, this dosimetric study showed that hybrid plans performed with 3D-CRT and VMAT techniques are feasible in terms of dosimetric outcomes.
| 2 |
Author(s):
Monica-Emilia.
Page No :
|
About Intelligence (Artificial or Not) – A Discussion with Marcel van Herk
Abstract
Professor Marcel van Herk is the chair of the radiotherapy physics at the University of Manchester. As a medical physics student he started on the development of a liquid ionization imaging device that later became the Varian PortalVision system for electronic portal imaging. Starting during a Postdoc at Harvard Medical School, USA in 1992, his work incorporated 3D image processing, first CT-MR image registration for treatment planning, later measuring organ motion and other uncertainties in radiotherapy such as delineation variability. Much of this work has been integrated in the Elekta Synergy cone-beam CT image guidance system developed. He also held a part-time teaching role as a Professor at the University of Amsterdam working amongst others at the integration of microscopic optical imaging into radiotherapy treatment planning. His goal is to do research to improve the clinical practice of radiotherapy.
| 3 |
Author(s):
Catalin Stefan , Livia Marieta , Stefania Maria, Mariana, Livia Carmen, Gabriel.
Page No : 18-26
|
REAL-WORLD SINGLE-CENTER CLINICAL DATA ON SORAFENIB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
Abstract
Introduction. Hepatocellular carcinoma (HCC) is a malignant tumor that frequently develops in conjunction with chronic liver disease and cirrhosis. It is often identified late in its course, with a median survival of around 6 to 20 months following diagnosis. Although surgical excision is the gold standard of treatment, the majority of patients are ineligible due to tumor size or underlying liver disease. The hepatic reserve of the patient, as determined by the Child-Turcotte-Pugh classification, frequently influences treatment options.
Method. Between January 2016 and June 2018, 42 patients admitted to Fundeni Clinical Institute's Department of Medical Oncology who had previously been treated with Sorafenib for more than two months were recruited in this retrospective analysis. We evaluated the etiology and stage of illness (BCLC), residual liver function (CHILD), performance status (ECOG), responsiveness to therapy and side events, progression-free survival, and overall survival.
Results. With a median progression-free survival of 7.7 months and a median overall survival of 11.6 months, the study group had good outcomes in both the short and long terms. Among the most often reported adverse effects were skin rashes, diarrhea and hypertension.
Conclusion. This retrospective, single-center study confirmed the benefit of sorafenib in the treatment of advanced HCC, particularly in patients with intact liver function and performance status.
